Initial test group shows 29 of 30 patients treated with new cancer drug recovered after being seriously ill with the China virus.
New Israeli drug may be world’s first to successfully treat Covid-19
By By Paul Shindman, World Israel News, February 5, 20201:
Initial test group shows 29 of 30 patients treated with new cancer drug recovered after being seriously ill with coronavirus.
Researchers at Tel Aviv’s Ichilov Hospital have discovered that a new cancer drug has been successfully used to treat patients seriously ill with the coronavirus, Kan News reported Friday.
The drug EXO-CD24 is based on a biological protein normally associated with cancer research that is known to calm the body’s immune system, which in the second stage of coronavirus attacks itself and causes severe breathing problems.
The treatment developed by Professor Nadir Arber of the Integrated Cancer Prevention Center at the hospital was tested on 30 patients in moderate and serious condition suffering from the virus with a 95% positive result.
Of the 30 patients in the test group, 29 showed a significant improvement within two days of receiving the drug and were released from the hospital three to five days later. Another patient also recovered, but took a few days longer, the hospital reported.
Arber said EXO-CD24 is inexpensive and is given once daily for five days, being introduced to the body using an inhalator so that the protein released in the lungs calms the immune system, which stops attacking itself and eases the respiratory suffering of the patients.
“To this day, despite endless efforts, there is no drug that has been proven effective in treating corona,” the hospital told Kan. “Even if the vaccines perform their function, and even if no new mutations are produced, then in one way or another the corona will remain with us.”
“EXO-CD24 is an innovative, blue-and-white, goal-oriented drug, developed on the basis of many years of research in Prof. Nadir Arber’s laboratory,” the hospital said, adding that the treatment is targeted at patients in serious condition in order to prevent their deterioration.
“The preparation is given locally, works extensively and has no side effects. It is an advanced preparation, which can be produced quickly and efficiently and at a very low cost, produced in any pharmaceutical facility in the country, and in a short time all global consumption can be supplied,” explained Prof. Arber.
The hospital requested Health Ministry permission to extend the trial to more patients, Ynet reported.
Have a tip we should know? Your anonymity is NEVER compromised. Email firstname.lastname@example.org
The Truth Must be Told
Your contribution supports independent journalism
Please take a moment to consider this. Now, more than ever, people are reading Geller Report for news they won't get anywhere else. But advertising revenues have all but disappeared. Google Adsense is the online advertising monopoly and they have banned us. Social media giants like Facebook and Twitter have blocked and shadow-banned our accounts. But we won't put up a paywall. Because never has the free world needed independent journalism more.
Everyone who reads our reporting knows the Geller Report covers the news the media won't. We cannot do our ground-breaking report without your support. We must continue to report on the global jihad and the left's war on freedom. Our readers’ contributions make that possible.
Geller Report's independent, investigative journalism takes a lot of time, money and hard work to produce. But we do it because we believe our work is critical in the fight for freedom and because it is your fight, too.
Please contribute here.
Make a monthly commitment to support The Geller Report – choose the option that suits you best.